Cardioprotective benefits of metabolic surgery and GLP-1 receptor agonist-based therapies.
代謝手術和GLP-1受體激動劑療法的心臟保護益處。
Trends Endocrinol Metab 2024-08-10
Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment.
糖尿病患者中主要不良心血管事件的發生率:一項全國性的 cohort 研究,比較原發性代謝手術和肥胖手術與 GLP-1 受體激動劑治療。
Int J Obes (Lond) 2023-05-10
Effectiveness of bariatric metabolic surgery versus glucagon-like peptide-1 receptor agonists for prevention of congestive heart failure.
肥胖代謝手術與葡萄糖樣肽-1 受體激動劑在預防充血性心臟衰竭方面的有效性。
Nat Med 2024-05-23
Renoprotective Effects of Metabolic Surgery Versus GLP1 Receptor Agonists on Progression of Kidney Impairment in Patients with Established Kidney Disease.
代謝手術與 GLP1 受體激動劑對已確診腎臟疾病患者腎功能惡化進展的腎保護效應。
Ann Surg 2024-06-11
Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs.
GLP-1 受體激動劑的心血管保護特性:不僅僅是糖尿病和減重藥物。
J Clin Med 2024-08-29
Cardiovascular and diabetes outcomes among patients with obesity and type 2 diabetes after metabolic bariatric surgery or glucagon-like peptide 1 receptor agonist treatment.
肥胖及第二型糖尿病患者在接受代謝性減重手術或胰高血糖素樣肽-1受體激動劑治療後的心血管及糖尿病結果。
Br J Surg 2024-09-05
這項研究比較了代謝性減重手術(如Roux-en-Y胃旁路手術和袖狀胃切除術)與胰高血糖素樣肽-1受體激動劑在2型糖尿病和肥胖患者中的效果,隨訪平均7年。結果顯示,手術組的重大心血管事件發生率較低(14.5% vs 19.6%),血紅素A1c水平顯著下降,且微血管併發症風險減少。然而,手術組也面臨較高的酒精/物質濫用、自我傷害和骨折風險。因此,雖然手術有助於改善代謝狀況,但需注意潛在的不良後果。
PubMedDOI
Evaluating Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) in Type 2 Diabetes Mellitus: A Systematic Review.
評估 GLP-1 受體激動劑 (GLP-1 RAs) 在 2 型糖尿病中的心血管益處:系統性回顧。
Cureus 2024-09-12